Celldex Therapeutics (CLDX)
Celldex Therapeutics on one page: short interest, daily short volume, fails to deliver, planned sales, large holders, 13F holders, financials, earnings dates and insider trades. Listed on Nasdaq, classified by the SEC as in vitro & in vivo diagnostic substances.
9.6M
Short interest
settlement 2026-10-15
5.9
Days to cover
+2.1 days vs prior
43.3%
Short share of volume
2026-11-03
222
Fails to deliver
settlement 2026-10-05
Mon 9 Nov
Next earnings
estimated date
$0
Insider flow, 90 days
0 buys, 0 sells
As of 2026-11-03.
Short interest
FINRA, twice a month. The newest 48 settlements in the table, 48 in the chart. JSONAs of 15 October 2026, short interest in CLDX is 9,598,891 shares, up 645,764 shares over the last month. Over the last 48 readings it ranged from 6,581,143 shares (15 September 2025) to 11,006,720 shares (30 September 2026). At the reported average volume of 1.6M shares a day that is 5.9 days to cover.
Embed this chart.The embed keeps its attribution line.
<iframe src="https://xoomar.com/embed/stocks/cldx" width="100%" height="440" style="border:0;max-width:100%" loading="lazy" title="XOOMAR chart"></iframe>
| Settlement | Shares short | Change | Avg daily volume | Days to cover |
|---|---|---|---|---|
| 2026-10-15 | 9,598,891 | -12.8% | 1,633,453 | 5.88 |
| 2026-09-30 | 11,006,720 | +22.9% | 2,886,493 | 3.81 |
| 2026-09-15 | 8,953,127 | +3.6% | 682,564 | 13.12 |
| 2026-08-31 | 8,641,597 | +14.2% | 706,596 | 12.23 |
| 2026-08-14 | 7,569,702 | -0.8% | 954,775 | 7.93 |
| 2026-07-31 | 7,627,081 | -0.5% | 1,001,184 | 7.62 |
| 2026-07-15 | 7,663,191 | -1.0% | 838,121 | 9.14 |
| 2026-06-30 | 7,738,673 | +6.1% | 1,799,211 | 4.30 |
| 2026-06-15 | 7,295,393 | +2.1% | 805,783 | 9.05 |
| 2026-05-29 | 7,144,877 | +0.2% | 665,613 | 10.73 |
| 2026-05-15 | 7,130,776 | -6.2% | 708,676 | 10.06 |
| 2026-04-30 | 7,599,353 | -8.5% | 807,986 | 9.41 |
| 2026-04-15 | 8,309,099 | -8.4% | 1,499,232 | 5.54 |
| 2026-03-31 | 9,075,800 | -1.8% | 1,068,463 | 8.49 |
| 2026-03-13 | 9,237,012 | +2.6% | 928,511 | 9.95 |
| 2026-02-27 | 9,006,071 | -1.9% | 1,067,518 | 8.44 |
| 2026-02-13 | 9,181,713 | -0.6% | 690,600 | 13.30 |
| 2026-01-30 | 9,237,135 | +2.2% | 475,721 | 19.42 |
| 2026-01-15 | 9,034,401 | +9.6% | 833,721 | 10.84 |
| 2025-12-31 | 8,244,450 | +20.1% | 672,703 | 12.26 |
| 2025-12-15 | 6,865,432 | -20.9% | 868,859 | 7.90 |
| 2025-11-28 | 8,675,509 | -1.9% | 653,720 | 13.27 |
| 2025-11-14 | 8,845,278 | +17.8% | 1,041,609 | 8.49 |
| 2025-10-31 | 7,509,487 | +1.5% | 721,028 | 10.41 |
| 2025-10-15 | 7,395,696 | +4.4% | 960,982 | 7.70 |
| 2025-09-30 | 7,083,741 | +7.6% | 1,174,444 | 6.03 |
| 2025-09-15 | 6,581,143 | -8.8% | 1,482,997 | 4.44 |
| 2025-08-29 | 7,214,984 | -1.3% | 1,763,380 | 4.09 |
| 2025-08-15 | 7,312,348 | -6.0% | 1,181,040 | 6.19 |
| 2025-07-31 | 7,781,241 | -8.1% | 890,155 | 8.74 |
| 2025-07-15 | 8,469,593 | +7.6% | 990,480 | 8.55 |
| 2025-06-30 | 7,873,818 | +0.6% | 1,120,201 | 7.03 |
| 2025-06-13 | 7,828,519 | -6.5% | 1,284,825 | 6.09 |
| 2025-05-30 | 8,370,585 | -8.3% | 1,090,380 | 7.68 |
| 2025-05-15 | 9,127,147 | +1.3% | 744,502 | 12.26 |
| 2025-04-30 | 9,009,066 | +2.6% | 641,049 | 14.05 |
| 2025-04-15 | 8,779,950 | +5.7% | 992,432 | 8.85 |
| 2025-03-31 | 8,303,305 | -9.3% | 748,063 | 11.10 |
| 2025-03-14 | 9,151,823 | +3.1% | 817,555 | 11.19 |
| 2025-02-28 | 8,875,878 | -3.5% | 641,501 | 13.84 |
| 2025-02-14 | 9,192,670 | +3.6% | 859,800 | 10.69 |
| 2025-01-31 | 8,873,582 | +4.6% | 790,546 | 11.22 |
| 2025-01-15 | 8,480,235 | +4.9% | 1,366,662 | 6.21 |
| 2024-12-31 | 8,086,627 | +10.7% | 816,361 | 9.91 |
| 2024-12-13 | 7,308,344 | -5.1% | 981,184 | 7.45 |
| 2024-11-29 | 7,701,959 | -1.7% | 1,092,436 | 7.05 |
| 2024-11-15 | 7,834,833 | -4.9% | 1,125,324 | 6.96 |
| 2024-10-31 | 8,239,830 | -1.9% | 964,822 | 8.54 |
Daily short volume
FINRA Reg SHO, the last 30 sessions. JSONAs of 3 November 2026, the short share of CLDX volume is 43.3%, down 0.1 points over the last five sessions. Over the last 30 readings it ranged from 24.3% (13 October 2026) to 83.1% (23 October 2026). The latest reading is 12.7 points below the 30-session average of 56.0%, on 380K shares reported.
| Date | Short volume | Total volume | Short share | Exempt |
|---|---|---|---|---|
| 2026-11-03 | 165K | 380K | 43.3% | 820 |
| 2026-11-02 | 205K | 283K | 72.6% | 101 |
| 2026-10-30 | 160K | 221K | 72.3% | 0 |
| 2026-10-29 | 207K | 406K | 51.1% | 8,675 |
| 2026-10-28 | 242K | 390K | 61.9% | 0 |
| 2026-10-27 | 139K | 321K | 43.4% | 0 |
| 2026-10-26 | 133K | 198K | 67.1% | 0 |
| 2026-10-23 | 291K | 351K | 83.1% | 0 |
| 2026-10-22 | 123K | 249K | 49.2% | 0 |
| 2026-10-21 | 238K | 423K | 56.2% | 0 |
| 2026-10-20 | 197K | 354K | 55.6% | 52 |
| 2026-10-19 | 308K | 632K | 48.7% | 10 |
| 2026-10-16 | 278K | 351K | 79.3% | 1 |
| 2026-10-15 | 242K | 471K | 51.5% | 20 |
| 2026-10-14 | 188K | 361K | 52.0% | 0 |
| 2026-10-13 | 197K | 811K | 24.3% | 0 |
| 2026-10-12 | 139K | 204K | 68.2% | 0 |
| 2026-10-09 | 124K | 282K | 44.0% | 0 |
| 2026-10-08 | 406K | 1.5M | 27.6% | 0 |
| 2026-10-07 | 231K | 461K | 50.1% | 0 |
| 2026-10-06 | 513K | 858K | 59.8% | 1 |
| 2026-10-05 | 232K | 400K | 58.1% | 15 |
| 2026-10-02 | 517K | 1.4M | 37.8% | 0 |
| 2026-10-01 | 390K | 632K | 61.6% | 752 |
| 2026-09-30 | 345K | 536K | 64.3% | 60 |
| 2026-09-29 | 309K | 805K | 38.4% | 0 |
| 2026-09-28 | 455K | 709K | 64.2% | 0 |
| 2026-09-25 | 601K | 897K | 67.0% | 0 |
| 2026-09-24 | 605K | 904K | 67.0% | 0 |
| 2026-09-23 | 1.4M | 2.3M | 60.5% | 30,864 |
Fails to deliver
SEC, the last 30 settlement dates with a fail. JSONAs of 5 October 2026, the fails-to-deliver balance in CLDX is 222 shares, up 220 shares over the last settlement date. Over the last 30 readings it ranged from 2 shares (30 September 2026) to 54,085 shares (1 September 2026). The latest reading sits at the bottom of that range.
| Settlement | Shares failed | Price | Value |
|---|---|---|---|
| 2026-10-05 | 222 | $31.65 | $7K |
| 2026-09-30 | 2 | $31.64 | $63 |
| 2026-09-23 | 20,161 | $33.51 | $676K |
| 2026-09-15 | 24 | $39.18 | $940 |
| 2026-09-01 | 54,085 | $39.63 | $2.1M |
| 2026-08-18 | 1,202 | $41.92 | $50K |
| 2026-08-04 | 394 | $37.69 | $15K |
| 2026-07-28 | 140 | $35.65 | $5K |
| 2026-07-22 | 308 | $35.66 | $11K |
| 2026-07-20 | 151 | $35.35 | $5K |
| 2026-07-17 | 18 | $35.40 | $637 |
| 2026-07-02 | 673 | $36.78 | $25K |
| 2026-07-01 | 598 | $37.21 | $22K |
| 2026-06-30 | 10,049 | $37.44 | $376K |
| 2026-06-29 | 6,763 | $35.26 | $238K |
| 2026-06-26 | 3 | $34.09 | $102 |
| 2026-06-24 | 2,832 | $32.98 | $93K |
| 2026-06-12 | 219 | $29.96 | $7K |
| 2026-05-14 | 96 | $32.51 | $3K |
| 2026-04-28 | 12,625 | $33.66 | $425K |
| 2026-04-23 | 530 | $34.21 | $18K |
| 2026-04-20 | 100 | $34.55 | $3K |
| 2026-04-02 | 12,862 | $31.26 | $402K |
| 2026-03-23 | 192 | $30.90 | $6K |
| 2026-02-23 | 19,578 | $23.02 | $451K |
| 2026-02-17 | 3 | $23.00 | $69 |
| 2026-02-12 | 43,753 | $24.60 | $1.1M |
| 2026-02-03 | 487 | $24.66 | $12K |
| 2026-02-02 | 503 | $24.60 | $12K |
| 2026-01-23 | 662 | $26.85 | $18K |
Insider trades
SEC Form 4, newest first. JSONNo open-market insider trades were reported for CLDX in the last 90 days. The most recent filings are listed below. Latest filing: Martin Samuel Bates (SVP AND CFO) on 2026-01-02.
| Date | Insider | Title | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|---|
| 2026-01-02 | Martin Samuel Bates | SVP AND CFO | Exercise or conversion | 5K | $10.38 | $50K | 33K |
| 2025-12-15 | PEPIN RONALD | SR. VP & CBO | Exercise or conversion | 11K | $2.78 | $31K | 20K |
| 2025-12-15 | PEPIN RONALD | SR. VP & CBO | Exercise or conversion | 8K | $9.02 | $75K | 9K |
| 2025-12-04 | Jimenez Freddy A. | SVP & GENERAL COUNSEL | Sell | 4K | $29.09 | $121K | 31K |
| 2025-11-13 | Wright Richard M. | Former Officer | Sell | 49K | $24.00 | $1.2M | 21K |
| 2025-11-13 | Wright Richard M. | Former Officer | Exercise or conversion | 16K | $22.48 | $354K | 70K |
| 2025-11-13 | Wright Richard M. | Former Officer | Exercise or conversion | 27K | $10.38 | $277K | 54K |
| 2025-11-13 | Wright Richard M. | Former Officer | Exercise or conversion | 7K | $9.02 | $62K | 28K |
| 2025-08-13 | Jimenez Freddy A. | SVP & GENERAL COUNSEL | Sell | 430 | $25.41 | $11K | 35K |
| 2025-08-13 | Jimenez Freddy A. | SVP & GENERAL COUNSEL | Sell | 341 | $23.95 | $8K | 35K |
| 2024-11-18 | MARINO JAMES J | Director | Gift | 11K | $0.00 | $0 | 2K |
| 2024-11-11 | Marucci Anthony S | PRESIDENT & CEO | Buy | 12K | $26.82 | $308K | 40K |
| 2024-06-14 | Crowley Elizabeth | SR. VP & CPDO | Exercise or conversion | 30K | $10.38 | $311K | 39K |
| 2024-06-14 | Crowley Elizabeth | SR. VP & CPDO | Sell | 30K | $34.87 | $1.0M | 9K |
| 2024-06-14 | Martin Samuel Bates | SVP AND CFO | Exercise or conversion | 3K | $9.02 | $29K | 28K |
| 2024-06-14 | Martin Samuel Bates | SVP AND CFO | Exercise or conversion | 17K | $10.38 | $176K | 45K |
| 2024-06-14 | Martin Samuel Bates | SVP AND CFO | Sell | 17K | $35.42 | $608K | 28K |
| 2024-06-11 | Young Diane C. | SVP, CHIEF MEDICAL OFFICER | Exercise or conversion | 15K | $2.71 | $41K | 17K |
| 2024-06-07 | Crowley Elizabeth | SR. VP & CPDO | Exercise or conversion | 8K | $10.38 | $78K | 17K |
| 2024-06-07 | Young Diane C. | SVP, CHIEF MEDICAL OFFICER | Sell | 45K | $35.26 | $1.6M | 2K |
| 2024-06-07 | Crowley Elizabeth | SR. VP & CPDO | Sell | 15K | $35.06 | $526K | 9K |
| 2024-06-07 | Crowley Elizabeth | SR. VP & CPDO | Exercise or conversion | 8K | $9.02 | $68K | 24K |
| 2024-06-05 | Jimenez Freddy A. | SVP & GENERAL COUNSEL | Exercise or conversion | 10K | $10.38 | $99K | 35K |
| 2024-06-03 | Jimenez Freddy A. | SVP & GENERAL COUNSEL | Sell | 8K | $33.60 | $269K | 26K |
| 2024-06-03 | Jimenez Freddy A. | SVP & GENERAL COUNSEL | Exercise or conversion | 8K | $10.38 | $83K | 34K |
| 2024-06-03 | Wright Richard M. | SR. VP & CCO | Exercise or conversion | 28K | $28.00 | $797K | 49K |
| 2024-06-03 | Wright Richard M. | SR. VP & CCO | Sell | 19K | $33.99 | $655K | 21K |
| 2024-06-03 | Wright Richard M. | SR. VP & CCO | Exercise or conversion | 21K | $2.78 | $57K | 21K |
| 2024-06-03 | Wright Richard M. | SR. VP & CCO | Sell | 28K | $33.53 | $925K | 40K |
| 2024-06-03 | Wright Richard M. | SR. VP & CCO | Exercise or conversion | 18K | $22.48 | $413K | 68K |
| 2024-06-03 | Heath-Chiozzi Margo | SVP OF REGULATORY AFFAIRS | Sell | 58K | $33.65 | $2.0M | 13K |
| 2024-06-03 | Heath-Chiozzi Margo | SVP OF REGULATORY AFFAIRS | Exercise or conversion | 58K | $10.38 | $606K | 72K |
| 2024-06-03 | Heath-Chiozzi Margo | SVP OF REGULATORY AFFAIRS | Exercise or conversion | 6K | $9.02 | $57K | 13K |
| 2024-05-30 | Crowley Elizabeth | SR. VP & CPDO | Sell | 39K | $33.64 | $1.3M | 9K |
| 2024-05-30 | Crowley Elizabeth | SR. VP & CPDO | Exercise or conversion | 34K | $2.78 | $96K | 39K |
| 2024-05-30 | Crowley Elizabeth | SR. VP & CPDO | Exercise or conversion | 9K | $9.02 | $77K | 48K |
| 2024-05-30 | Cavanaugh Sarah | SVP OF CORP AFFAIRS & ADMIN. | Exercise or conversion | 11K | $2.78 | $30K | 13K |
| 2024-05-30 | Cavanaugh Sarah | SVP OF CORP AFFAIRS & ADMIN. | Exercise or conversion | 10K | $9.02 | $91K | 23K |
| 2024-05-30 | Cavanaugh Sarah | SVP OF CORP AFFAIRS & ADMIN. | Sell | 21K | $33.73 | $703K | 2K |
| 2024-05-30 | Martin Samuel Bates | SVP AND CFO | Exercise or conversion | 25K | $10.38 | $260K | 60K |
| 2024-05-30 | Martin Samuel Bates | SVP AND CFO | Sell | 35K | $34.05 | $1.2M | 25K |
| 2024-05-30 | Heath-Chiozzi Margo | SVP OF REGULATORY AFFAIRS | Sell | 39K | $34.07 | $1.3M | 7K |
| 2024-05-30 | Heath-Chiozzi Margo | SVP OF REGULATORY AFFAIRS | Exercise or conversion | 29K | $2.78 | $81K | 41K |
| 2024-05-30 | Heath-Chiozzi Margo | SVP OF REGULATORY AFFAIRS | Exercise or conversion | 2K | $9.02 | $18K | 43K |
| 2024-05-30 | Heath-Chiozzi Margo | SVP OF REGULATORY AFFAIRS | Exercise or conversion | 3K | $10.38 | $27K | 46K |
| 2024-02-13 | Jimenez Freddy A. | SVP & GENERAL COUNSEL | Exercise or conversion | 20K | $2.78 | $56K | 26K |
| 2024-02-13 | Jimenez Freddy A. | SVP & GENERAL COUNSEL | Exercise or conversion | 4K | $9.02 | $38K | 6K |
| 2024-01-02 | Martin Samuel Bates | SVP AND CFO | Exercise or conversion | 11K | $2.78 | $30K | 35K |
| 2022-12-07 | KELER TIBOR | EXECUTIVE VP & CSO | Exercise or conversion | 17K | $2.78 | $47K | 24K |
| 2022-12-07 | KELER TIBOR | EXECUTIVE VP & CSO | Sell | 17K | $36.93 | $623K | 7K |
| 2022-08-18 | Cavanaugh Sarah | SVP OF CORP AFFAIRS & ADMIN. | Sell | 1K | $36.38 | $49K | 1K |
| 2022-08-18 | Cavanaugh Sarah | SVP OF CORP AFFAIRS & ADMIN. | Exercise or conversion | 1K | $9.02 | $12K | 3K |
| 2022-08-17 | Young Diane C. | SVP, CHIEF MEDICAL OFFICER | Exercise or conversion | 19K | $10.38 | $197K | 21K |
| 2022-08-17 | Young Diane C. | SVP, CHIEF MEDICAL OFFICER | Sell | 19K | $37.30 | $709K | 2K |
| 2022-08-17 | Young Diane C. | SVP, CHIEF MEDICAL OFFICER | Exercise or conversion | 45K | $2.71 | $122K | 47K |
| 2022-08-17 | Cavanaugh Sarah | SVP OF CORP AFFAIRS & ADMIN. | Exercise or conversion | 31K | $2.78 | $87K | 33K |
| 2022-08-17 | Cavanaugh Sarah | SVP OF CORP AFFAIRS & ADMIN. | Sell | 31K | $36.73 | $1.2M | 1K |
| 2022-08-15 | Wright Richard M. | SR. VP & CCO | Exercise or conversion | 15K | $10.38 | $159K | 16K |
| 2022-08-15 | Wright Richard M. | SR. VP & CCO | Sell | 15K | $37.71 | $578K | 208 |
| 2022-08-15 | Marucci Anthony S | PRESIDENT & CEO | Exercise or conversion | 45K | $9.02 | $406K | 148K |
| 2022-08-15 | Marucci Anthony S | PRESIDENT & CEO | Exercise or conversion | 75K | $2.78 | $209K | 103K |
| 2022-08-15 | Marucci Anthony S | PRESIDENT & CEO | Sell | 120K | $37.66 | $4.5M | 28K |
| 2022-08-12 | Martin Samuel Bates | SVP AND CFO | Exercise or conversion | 14K | $2.78 | $38K | 42K |
| 2022-08-12 | Martin Samuel Bates | SVP AND CFO | Sell | 2K | $35.38 | $73K | 26K |
| 2022-08-12 | Martin Samuel Bates | SVP AND CFO | Exercise or conversion | 4K | $9.02 | $35K | 28K |
| 2022-08-12 | Martin Samuel Bates | SVP AND CFO | Sell | 1K | $34.62 | $42K | 24K |
| 2022-08-12 | Martin Samuel Bates | SVP AND CFO | Sell | 14K | $36.76 | $524K | 28K |
| 2022-08-11 | Martin Samuel Bates | SVP AND CFO | Exercise or conversion | 2K | $9.02 | $22K | 27K |
| 2022-08-11 | Martin Samuel Bates | SVP AND CFO | Sell | 2K | $37.04 | $91K | 24K |
| 2021-12-23 | Martin Samuel Bates | SVP and CFO | Exercise or conversion | 4K | $2.78 | $10K | 34K |
| 2021-12-23 | Martin Samuel Bates | SVP and CFO | Sell | 10K | $42.00 | $399K | 24K |
| 2021-12-23 | Martin Samuel Bates | SVP and CFO | Exercise or conversion | 3K | $9.02 | $29K | 30K |
| 2021-12-08 | Heath-Chiozzi Margo | SVP of Regulatory Affairs | Sell | 600 | $40.00 | $24K | 11K |
| 2021-12-08 | Heath-Chiozzi Margo | SVP of Regulatory Affairs | Exercise or conversion | 600 | $2.78 | $2K | 12K |
| 2021-12-08 | Crowley Elizabeth | Sr. VP &CPDO | Sell | 4K | $40.00 | $160K | 5K |
| 2021-12-08 | Crowley Elizabeth | Sr. VP &CPDO | Exercise or conversion | 4K | $9.02 | $36K | 9K |
| 2021-12-08 | Cavanaugh Sarah | SVP of Corp Affairs & Admin. | Exercise or conversion | 5K | $10.38 | $57K | 8K |
| 2021-12-08 | Cavanaugh Sarah | SVP of Corp Affairs & Admin. | Sell | 7K | $40.00 | $293K | 408 |
| 2021-12-08 | Cavanaugh Sarah | SVP of Corp Affairs & Admin. | Exercise or conversion | 2K | $9.02 | $17K | 2K |
| 2021-11-15 | Martin Samuel Bates | SVP and CFO | Sell | 7K | $43.92 | $327K | 29K |
| 2021-11-15 | Martin Samuel Bates | SVP and CFO | Exercise or conversion | 4K | $2.78 | $10K | 36K |
| 2021-11-15 | Martin Samuel Bates | SVP and CFO | Exercise or conversion | 3K | $9.02 | $29K | 33K |
| 2021-11-15 | Martin Samuel Bates | SVP and CFO | Sell | 2K | $42.27 | $87K | 27K |
| 2021-11-12 | Young Diane C. | SVP, Chief Medical Officer | Exercise or conversion | 5K | $10.38 | $48K | 7K |
| 2021-11-12 | Young Diane C. | SVP, Chief Medical Officer | Sell | 5K | $42.94 | $198K | 2K |
| 2021-11-01 | Heath-Chiozzi Margo | SVP of Regulatory Affairs | Sell | 600 | $41.71 | $25K | 11K |
| 2021-11-01 | Heath-Chiozzi Margo | SVP of Regulatory Affairs | Exercise or conversion | 600 | $2.78 | $2K | 12K |
| 2021-11-01 | Crowley Elizabeth | Sr. VP &CPDO | Sell | 3K | $44.12 | $112K | 7K |
| 2021-11-01 | Crowley Elizabeth | Sr. VP &CPDO | Exercise or conversion | 9K | $2.78 | $24K | 9K |
| 2021-11-01 | Crowley Elizabeth | Sr. VP &CPDO | Sell | 600 | $43.11 | $26K | 6K |
| 2021-11-01 | Crowley Elizabeth | Sr. VP &CPDO | Sell | 1K | $41.62 | $49K | 5K |
| 2021-11-01 | Cavanaugh Sarah | SVP of Corp Affairs & Admin. | Exercise or conversion | 938 | $2.78 | $3K | 8K |
| 2021-11-01 | Cavanaugh Sarah | SVP of Corp Affairs & Admin. | Sell | 4K | $44.11 | $190K | 3K |
| 2021-11-01 | Cavanaugh Sarah | SVP of Corp Affairs & Admin. | Sell | 2K | $41.62 | $88K | 408 |
| 2021-11-01 | Cavanaugh Sarah | SVP of Corp Affairs & Admin. | Sell | 901 | $43.06 | $39K | 3K |
| 2021-11-01 | Cavanaugh Sarah | SVP of Corp Affairs & Admin. | Exercise or conversion | 5K | $9.02 | $45K | 7K |
| 2021-08-11 | Jimenez Freddy A. | SVP & General Counsel | Buy | 430 | $46.28 | $20K | 430 |
| 2021-08-11 | Heath-Chiozzi Margo | SVP of Regulatory Affairs | Exercise or conversion | 10K | $9.02 | $90K | 11K |
| 2021-08-10 | Martin Samuel Bates | SVP and CFO | Sell | 682 | $45.25 | $31K | 29K |
| 2021-08-10 | Martin Samuel Bates | SVP and CFO | Exercise or conversion | 11K | $2.78 | $31K | 30K |
Form 4 filings are due within two business days of the trade. Insiders sell for many reasons that say nothing about the company; open-market buys are rarer.
Planned sales (Form 144)
Newest first. JSON2 Form 144 notices on file for CLDX worth $1.3M at the prices reported; 0 in the last 90 days worth $0. Latest: FREDDY A JIMENEZ filed on 2025-12-04 to sell 4,166 shares ($121K) from 2025-12-04.
| Filed | Seller | Shares | Market value | Of outstanding | Sale from | Broker |
|---|---|---|---|---|---|---|
| 2025-12-04 | FREDDY A JIMENEZOfficer | 4K | $121K | 0.006% | 2025-12-04 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2025-11-13 | RICHARD M WRIGHTOfficer | 49K | $1.2M | 0.074% | 2025-11-13 | Morgan Stanley Smith Barney LLC Executive Financial Services |
Large holders (13D and 13G)
One row per reporting person with its latest filing, newest first. JSON11 holders report 5% or more of CLDX in their latest filing, all on Schedule 13G (passive). The largest reported stake is Wellington Management Group LLP at 12.2% of the class (8,079,608 shares), filed 2026-02-10 for an event on 2025-12-31.
| Filed | Form | Holder | Shares | Of class | Event |
|---|---|---|---|---|---|
| 2026-10-07 | 13G/Ano. 7 | FMR LLCparent holding company | 8.4M | 10.7% | 2026-09-30 |
| 2026-10-07 | 13G/Ano. 7 | Abigail P. Johnsonindividual | 8.4M | 10.7% | 2026-09-30 |
| 2026-08-14 | 13G/Ano. 4 | Kynam Capital Management, LPinvestment adviser | 0 | 6.8% | 2026-06-30 |
| 2026-08-14 | 13G/Ano. 4 | Kynam Capital Management GP, LLCother entity | 0 | 6.8% | 2026-06-30 |
| 2026-08-14 | 13G/Ano. 4 | Yue Tangindividual | 0 | 6.8% | 2026-06-30 |
| 2026-08-14 | 13G | T. Rowe Price Associates, Inc.investment adviser | 4.7M | 6.0% | 2026-06-30 |
| 2026-05-15 | 13G/Ano. 1 | Bellevue Asset Management AGcorporation | 1.2M | 1.5% | 2026-03-31 |
| 2026-05-15 | 13G/Ano. 1 | Bellevue Group AGparent holding company, corporation | 1.2M | 1.5% | 2026-03-31 |
| 2026-05-12 | 13G | STATE STREET CORPORATIONparent holding company | 2.8M | 4.2% | 2026-03-31 |
| 2026-04-29 | 13G | Vanguard Capital Managementinvestment adviser | 3.4M | 5.2% | 2026-03-31 |
| 2026-03-26 | 13G/Ano. 3 | The Vanguard Groupinvestment adviser | 0 | 0.0% | 2026-03-13 |
| 2026-03-10 | 13G/Ano. 1 | Point72 Asset Management, L.P.partnership | 1.8M | 2.6% | 2025-12-31 |
| 2026-03-10 | 13G/Ano. 1 | Point72 Capital Advisors, Inc.corporation | 1.8M | 2.6% | 2025-12-31 |
| 2026-03-10 | 13G/Ano. 1 | Steven A. Cohenindividual | 1.8M | 2.6% | 2025-12-31 |
| 2026-02-10 | 13G/Ano. 7 | Wellington Management Group LLPparent holding company | 8.1M | 12.2% | 2025-12-31 |
| 2026-02-10 | 13G/Ano. 7 | Wellington Group Holdings LLPparent holding company | 8.1M | 12.2% | 2025-12-31 |
| 2026-02-10 | 13G/Ano. 7 | Wellington Investment Advisors Holdings LLPparent holding company | 8.1M | 12.2% | 2025-12-31 |
| 2026-02-10 | 13G/Ano. 7 | Wellington Management Company LLPinvestment adviser | 8.1M | 11.8% | 2025-12-31 |
| 2025-11-14 | 13G/Ano. 1 | Commodore Capital LPinvestment adviser, partnership | 3.0M | 4.6% | 2025-09-30 |
| 2025-11-14 | 13G/Ano. 1 | Commodore Capital Master LPpartnership | 3.0M | 4.6% | 2025-09-30 |
13F holders
Tracked managers holding CLDX at their latest 13F. JSON6 of the 30 tracked managers held CLDX at their latest 13F, $113.1M in total at quarter-end prices. Millennium Management is the largest at $43.6M (0.0% of its portfolio) as of 2026-06-30. Over the prior quarter 2 added shares and 4 cut.
| Fund | Quarter | Shares | Value | Of portfolio | Change in shares |
|---|---|---|---|---|---|
| Millennium Management | 2026-06-30 | 1.2M | $43.6M | 0.02% | -83K |
| Fisher Asset Management | 2026-06-30 | 986K | $36.7M | 0.01% | -28K |
| Two Sigma Investments | 2026-06-30 | 661K | $24.6M | 0.02% | +524K |
| Point72 Asset Management | 2026-06-30 | 117K | $4.4M | 0.00% | -3.1M |
| AQR Capital Management | 2026-06-30 | 87K | $3.2M | 0.00% | +79K |
| D. E. Shaw & Co. | 2026-06-30 | 18K | $663K | 0.00% | -35K |
Only the 30 tracked managers on the funds hub; a 13F reports long positions in US listed stock at quarter end, 45 days late, and says nothing about shorts or positions sold since.
Financials
SEC XBRL, as filed. JSONIn Q2 FY 2026 (quarter ended 2026-06-30) Celldex Therapeutics reported revenue of $22K, down 97.0% from the same quarter a year earlier, and net loss of $73.5M (-0.94 diluted EPS). In FY 2025 it generated -$210.9M of operating cash flow.
- Cash
- $47.5M
- Equity
- $714.6M
- Total assets
- $782.3M
- Shares outstanding
- 78,529,532
Quarterly, last 8 quarters
| Quarter | Period end | Revenue | Net income | Margin | Diluted EPS |
|---|---|---|---|---|---|
| Q2 FY 2026 | 2026-06-30 | $22K | -$73.5M | -334104.5% | -0.94 |
| Q1 FY 2026 | 2026-03-31 | $15K | -$78.7M | -524566.7% | -1.18 |
| Q4 FY 2025derived | 2025-12-31 | n/a | -$81.3M | n/a | n/a |
| Q3 FY 2025 | 2025-09-30 | n/a | -$67.0M | n/a | -1.01 |
| Q2 FY 2025 | 2025-06-30 | $730K | -$56.6M | -7753.4% | -0.85 |
| Q1 FY 2025 | 2025-03-31 | $695K | -$53.8M | -7740.4% | -0.81 |
| Q4 FY 2024derived | 2024-12-31 | $1.2M | -$47.1M | -4007.8% | n/a |
| Q3 FY 2024 | 2024-09-30 | $3.2M | -$42.1M | -1320.0% | -0.64 |
Fiscal years, with buybacks and dividends
| Fiscal year | Ends | Revenue | Net income | Operating cash flow | Capex | Buybacks | Dividends |
|---|---|---|---|---|---|---|---|
| FY 2025 | 2025-12-31 | $1.5M | -$258.8M | -$210.9M | $2.7M | n/a | n/a |
| FY 2024 | 2024-12-31 | $7.0M | -$157.9M | -$157.8M | $1.9M | n/a | n/a |
| FY 2023 | 2023-12-31 | $6.9M | -$141.4M | -$107.3M | $1.8M | n/a | n/a |
| FY 2022 | 2022-12-31 | $2.4M | -$112.3M | -$103.7M | $1.8M | n/a | n/a |
| FY 2021 | 2021-12-31 | $4.7M | -$70.5M | -$60.9M | $1.2M | n/a | n/a |
Quarters are the three-month figures the company reports; a fourth quarter marked derived is the fiscal year less the three reported quarters, since companies report it only inside the 10-K. Fiscal years are the annual figures. Buybacks are the cash the company paid to repurchase its common stock in the year, not the amount authorized. Balance sheet lines are as of 2026-06-30; shares outstanding as of 2026-07-29 from the cover page.
What this page is
Celldex Therapeutics in the regulatory record
Regulators publish company data in separate files that never sit next to each other: FINRA's twice-monthly short interest, its daily short sale volume, the SEC's fails-to-deliver counts, and each insider's Form 4. A company page puts those series for one ticker on one URL, with planned sales, large holders, 13F holders and financials beside them, so the short position, the daily flow, the settlement fails and what insiders are doing can be read together.
Each section has its own history table, a one-line summary of the latest figures and its own JSON and CSV links, and says when its source last updated.
This page follows Celldex Therapeutics (CLDX), SEC CIK 744218, listed on Nasdaq, classified by the SEC as in vitro & in vivo diagnostic substances. The cross-market tables live on the short interest and insider transactions hubs.
Source and updates
- Short interest
- FINRA consolidated short interestSource: FINRA.Twice a month, about eight business days after settlement. Latest 2026-10-15.JSON and CSV
- Daily short volume
- FINRA Reg SHO daily filesSource: FINRA.Every trading day, the morning after FINRA posts it. Latest 2026-11-03.JSON and CSV
- Fails to deliver
- SEC fails-to-deliver dataSource: SEC.Twice a month, a few weeks after the half month ends. Latest 2026-10-05.JSON and CSV
- Planned sales
- SEC EDGAR Form 144Source: SEC.New notices appear shortly after the SEC posts them; a notice is filed on or before the sale. Latest 2025-12-04.JSON and CSV
- Large holders
- SEC EDGAR Schedule 13D and 13GSource: SEC.New filings appear shortly after the SEC posts them. A 13D is due within five business days of crossing 5%; a 13G follows the passive schedule. Latest 2026-10-07.JSON and CSV
- 13F holders
- SEC EDGAR Form 13F-HRSource: SEC.Quarterly, filed within 45 days of quarter end; 30 tracked managers. Latest 2026-06-30.JSON and CSV
- Financials
- SEC EDGAR 10-K and 10-Q filingsSource: SEC.Weekly; values are as filed in the 10-Q and 10-K. Latest 2026-06-30.JSON and CSV
- Earnings dates
- SEC EDGAR 8-K filings (Item 2.02)Source: SEC.Twice a day. Reported dates come from the company's 8-K filings; the next date is marked as an estimate until the 8-K arrives. Latest 2026-08-06.JSON and CSV
- Insider trades
- SEC EDGAR Form 4Source: SEC.New filings appear shortly after the SEC posts them; they're due two business days after the trade. Latest 2026-01-02.JSON and CSV
- Company record
- EDGAR filing index for CIK 744218Ticker, name and exchange from the SEC's company list, refreshed weekly.
- Rate limits
- 10 requests a minute without a key, 30 with a free key from a free account.
How to read it
- Read the position against the flow: rising short interest with a high daily short share is new shorting; rising short interest with a normal short share is old shorts holding on.
- Insider buys next to a large short position are rare and stand out; insider sells next to one are common and mean little.
- Fails to deliver matter relative to the float, not in absolute shares; a million failed shares in a mega cap is noise.
Analysis of what the data shows, not advice. XOOMAR does not recommend buying, selling or holding anything.
Other companies the SEC classifies as in vitro & in vivo diagnostic substances
Other company pages
Datasets
Frequently Asked Questions
How much of CLDX is sold short?
9,598,891 shares were held short at the 2026-10-15 settlement, 5.9 days of average volume. FINRA publishes the next count about eight business days after the 15th and the last business day of the month.
What is CLDX's daily short volume?
On 2026-11-03, 164,569 of the 380,412 CLDX shares reported to FINRA were sold short, 43.3% of the day's reported volume. Short volume is a flow for one day, not a position.
Does CLDX have fails to deliver?
The SEC's latest file shows 222 CLDX shares failed to deliver at settlement 2026-10-05. Fails are reported per settlement date and published twice a month with a lag.
Are CLDX insiders buying or selling?
No open-market insider trades were reported for CLDX in the last 90 days. The most recent filings are listed below. Latest filing: Martin Samuel Bates (SVP AND CFO) on 2026-01-02.
Have CLDX insiders filed to sell?
2 Form 144 notices on file for CLDX worth $1.3M at the prices reported; 0 in the last 90 days worth $0. Latest: FREDDY A JIMENEZ filed on 2025-12-04 to sell 4,166 shares ($121K) from 2025-12-04.
Who owns 5% or more of CLDX?
11 holders report 5% or more of CLDX in their latest filing, all on Schedule 13G (passive). The largest reported stake is Wellington Management Group LLP at 12.2% of the class (8,079,608 shares), filed 2026-02-10 for an event on 2025-12-31.
What did CLDX report last quarter?
In Q2 FY 2026 (quarter ended 2026-06-30) Celldex Therapeutics reported revenue of $22K, down 97.0% from the same quarter a year earlier, and net loss of $73.5M (-0.94 diluted EPS). In FY 2025 it generated -$210.9M of operating cash flow.
Which tracked 13F managers own CLDX?
6 of the 30 tracked 13F managers held CLDX shares at their latest filing, $113.1M in all. The largest: Izzy Englander's Millennium Management (1.2M shares, $43.6M), Ken Fisher's Fisher Asset Management (986K shares, $36.7M), Two Sigma Investments (661K shares, $24.6M), Steve Cohen's Point72 Asset Management (117K shares, $4.4M), Cliff Asness's AQR Capital Management (87K shares, $3.2M), D. E. Shaw & Co. (18K shares, $663K).
Data on this page is provided for informational purposes only and is not financial advice. See our editorial policy.